Moderna, Inc.

MRNA · NASDAQ · USD

Can Moderna replace a shrinking COVID vaccine business with flu, combination and cancer products fast enough to reach cash breakeven before its reserves run down?

Last 4 earnings calls · through Q2 FY2026

Bull case

  • New products replace COVID

    The bull case rests on a wave of newly approved products, from a second COVID shot to a flu-COVID combination, replacing revenue the original COVID vaccine is losing.

  • Cost cuts ahead of plan

    Management has taken costs out faster than it promised, which lowers the revenue needed to break even and gives the pipeline more time to produce results.

  • Cancer therapy as second leg

    Intismeran would give Moderna a cancer business unrelated to seasonal vaccination, and its five-year melanoma data are what the bull case for that option rests on.

  • European market opening

    Europe has been closed to the company for years, and the end of a competitor's pandemic contract plus new approvals create a large market to enter from 2027.

Bear case

  • COVID base keeps shrinking

    The bear case starts with a COVID business that keeps getting smaller as vaccination rates fall, so each new product has to replace a moving target of lost sales.

  • Pipeline setbacks push out revenue

    The products meant to fill that gap have slipped: the CMV vaccine failed outright, norovirus needs another season, and flu and the combination contribute nothing yet.

  • Cash burn ahead of breakeven

    Even after deep cost cuts the company still spends more than it takes in, and the breakeven commitment is repeated less firmly as the launch dates move.

  • Unpredictable U.S. approvals

    U.S. regulators refused to file the flu vaccine once, and approval timing now depends on agency decisions the company does not control.

Bull and bear points

Growth & Execution

In short: New approvals and partnership orders are adding revenue, while the COVID base keeps shrinking.

Bull · 3

  • mNEXSPIKE takes U.S. COVID share on better data

    In its first season the new COVID shot took about 24% of U.S. retail COVID volume, so Moderna gained share even as total vaccinations fell.

    Q2 FY2026 call

  • European market reopens after 2026

    A competitor's pandemic supply contract kept Moderna out of Europe for years; it expires in 2026 and the flu-COVID combination is already approved there for the 2027 season.

    Q4 FY2025 call

  • Flu filing goes from refused to advisory backing

    Six months ago the FDA refused to file the flu vaccine; it now has a unanimous advisory committee recommendation and an August approval date, which puts a fifth product in reach.

    Tone shiftQ4 FY2025 → Q2 FY2026
Bear · 2

  • COVID vaccines still set total revenue

    COVID shots remain the large majority of sales, and total revenue fell 27.6% over the past twelve months, so share gains have not stopped the decline.

    Filed financials

  • Norovirus data slip to a third winter season

    Management expected Phase III norovirus data in 2026; the interim analysis missed its early-success bar and the trial now needs another season of case accrual.

    Tone shiftQ4 FY2025 → Q2 FY2026

Profitability & Financial Strength

In short: Cost cuts are ahead of plan and net cash is positive, while the company still spends more than it earns.

Bull · 2

  • Cash costs guided down to about $4 billion

    Management has lowered its 2026 cash cost target twice, to roughly $4 billion, which reduces the sales needed to cover the fixed base.

    Q2 FY2026 call

  • Net cash still funds the launch period

    Net cash stood at $4.5 billion in mid-2026, so the company can fund its fixed costs and launch spending without raising new equity.

    Filed financials
Bear · 2

  • Free cash flow remains firmly negative

    The company spent $1.2 billion more than it generated over the last twelve months, so reserves keep falling while the new products are still small.

    Filed financials

  • Breakeven date no longer restated

    A year ago management restated a 2028 cash breakeven target; after the flu filing refusal it said the timeline was too early to comment on, and later calls repeat only the annual cash cost goal.

    Tone shiftQ3 FY2025 → Q4 FY2025

Market Position

In short: The new COVID shot is winning share on better data, while U.S. policy and patent litigation limit the market.

Bull · 2

  • Real-world data favor mNEXSPIKE in seniors

    Effectiveness against hospitalization was about 59% in adults 65 and older, numerically above a competitor vaccine, which supports the product's position where most U.S. volume sits.

    Q2 FY2026 call

  • Intismeran has no approved competitor

    The individualized cancer therapy showed roughly a halved rate of relapse or death at five years in adjuvant melanoma, and Merck runs the Phase III and would file it.

    Q4 FY2025 call
Bear · 2

  • U.S. COVID vaccination rates keep falling

    U.S. retail vaccinations ran about 30% below the prior season, and recommendations have narrowed toward older and high-risk adults, which shrinks the market whatever the share.

    Q3 FY2025 call

  • Patent settlement carries a further contingent payment

    Moderna will pay Arbutus $950 million in the third quarter of 2026 and could owe up to $1.3 billion more if its government-contractor immunity appeal fails.

    Q1 FY2026 call